Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects

Molecular Aspects of Medicine
M E Rubio-GozalboR J A Wanders

Abstract

The carnitine-acylcarnitine translocase (CACT) is one of the components of the carnitine cycle. The carnitine cycle is necessary to shuttle long-chain fatty acids from the cytosol into the intramitochondrial space where mitochondrial beta-oxidation of fatty acids takes place. The oxidation of fatty acids yields acetyl-coenzyme A (CoA) units, which may either be degraded to CO(2) and H(2)O in the citric acid cycle to produce ATP or converted into ketone bodies which occurs in liver and kidneys. Metabolic consequences of a defective CACT are hypoketotic hypoglycaemia under fasting conditions, hyperammonemia, elevated creatine kinase and transaminases, dicarboxylic aciduria, very low free carnitine and an abnormal acylcarnitine profile with marked elevation of the long-chain acylcarnitines. Clinical signs and symptoms in CACT deficient patients, are a combination of energy depletion and endogenous toxicity. The predominantly affected organs are brain, heart and skeletal muscle, and liver, leading to neurological abnormalities, cardiomyopathy and arrythmias, skeletal muscle damage and liver dysfunction. Most patients become symptomatic in the neonatal period with a rapidly progressive deterioration and a high mortality rate. Howeve...Continue Reading

Citations

Jul 4, 2008·Archives of Toxicology·Hossam M M Arafa
May 13, 2009·Nature Reviews. Genetics·Derek Lessing, Nancy M Bonini
Jun 26, 2001·Seminars in Dialysis·S Ahmad
Apr 22, 2011·The New England Journal of Medicine·Marsha Kay FearingMikhail Lisovsky
Oct 5, 2010·Eukaryotic Cell·Karin Strijbis, Ben Distel
Jun 5, 2012·Circulation. Cardiovascular Genetics·Catherine O JohnsonThomas D Rea
Jul 28, 2010·European Journal of Pediatrics·Karim BouchirebLoic de Pontual
May 12, 2009·Cellular and Molecular Life Sciences : CMLS·Arne C RuferMichael Hennig
Mar 5, 2016·Journal of Applied Toxicology : JAT·Laura K SchnackenbergVarsha G Desai
Sep 15, 2009·Biochemical and Biophysical Research Communications·Keisuke TachibanaTakefumi Doi
Feb 24, 2009·Pathology, Research and Practice·Anne Marie LamhonwahIngrid Tein
Jun 20, 2007·Brain & Development·Anne Marie LamhonwahIngrid Tein
Nov 1, 2015·The Canadian Journal of Cardiology·Catherine Brunel-GuittonFlorin Sasarman
Mar 23, 2010·IUBMB Life·Karin StrijbisBen Distel
May 18, 2005·Molecular Genetics and Metabolism·Nadia A OeyRonald J A Wanders
Oct 31, 2014·The British Journal of Dermatology·A EspañaP Briones
May 6, 2014·Cell Metabolism·Laurent MouchiroudJohan Auwerx
Jun 16, 2015·Frontiers in Cell and Developmental Biology·Celien LismontMarc Fransen
Oct 25, 2011·Molecular Aspects of Medicine·Cesare IndiveriFerdinando Palmieri
Jun 21, 2012·Biochemical and Biophysical Research Communications·Mar GaciasJoana Relat
Apr 8, 2006·American Journal of Medical Genetics. Part C, Seminars in Medical Genetics·Nicola LongoMarzia Pasquali
Jun 10, 2006·Briefings in Bioinformatics·Pedro LarrañagaVictor Robles
Oct 17, 2009·Brain Injury : [BI]·Marie-Christine RousseauEstelle Bugni
Jan 21, 2020·Modern Rheumatology·Ichiro KobayashiMasaaki Mori
Feb 10, 2018·Journal of Pediatric Endocrinology & Metabolism : JPEM·Anita MacDonaldSaikat Santra
Sep 7, 2018·Experimental and Therapeutic Medicine·Guo-Xing WanYong-Gang Zhang
Sep 11, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mohammed AlmannaiAyman W El-Hattab
Jan 9, 2021·Clinical Chemistry·Mohammed AlmannaiNaif A M Almontashiri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.